Business Description
Abeona Therapeutics is a US-based biopharmaceutical company focused on developing gene and cell therapies for serious, life-threatening conditions. Its leading product, ZEVASKYN, is designed to treat recessive dystrophic epidermolysis bullosa, a severe skin disorder, while its pipeline includes additional therapies targeting rare eye diseases such as X-linked retinoschisis, Stargardt disease, and autosomal dominant optic atrophy. Founded in 1974 and headquartered in Cleveland, Ohio, the company also advances a broader gene therapy platform aimed at addressing other difficult-to-treat conditions.
